PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
242.97%
Revenue growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.24%. Joel Greenblatt would verify if operating margins keep pace with this top-line surge.
191.95%
Gross profit growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.18%. Joel Greenblatt would check if cost advantages or brand equity drive this surge.
-318.21%
Negative EBIT growth while Drug Manufacturers - Specialty & Generic median is 1.79%. Seth Klarman would check if external or internal factors caused the decline.
-318.21%
Negative operating income growth while Drug Manufacturers - Specialty & Generic median is 0.06%. Seth Klarman would check if structural or cyclical issues are at play.
-299.52%
Negative net income growth while Drug Manufacturers - Specialty & Generic median is 4.64%. Seth Klarman would investigate factors dragging net income down.
-295.00%
Negative EPS growth while Drug Manufacturers - Specialty & Generic median is 8.28%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-295.00%
Negative diluted EPS growth while Drug Manufacturers - Specialty & Generic median is 8.31%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
2.15%
Share growth above Drug Manufacturers - Specialty & Generic median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
0.34%
Diluted share growth above 2x Drug Manufacturers - Specialty & Generic median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
-1249.62%
Negative OCF growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-27.33%
Negative FCF growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
28238.49%
5Y revenue/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 8.12%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
545.67%
3Y revenue/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.24%. Joel Greenblatt might see a short-term competitive advantage at play.
-187.04%
Negative 10Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-89.89%
Negative 5Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-395.23%
Negative 3Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
-1405.06%
Negative 10Y net income/share CAGR vs. Drug Manufacturers - Specialty & Generic median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
-592.17%
Negative 5Y CAGR while Drug Manufacturers - Specialty & Generic median is -0.34%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-1081.80%
Negative 3Y CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
4146.76%
Equity/share CAGR of 4146.76% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
2334.22%
5Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 2.76%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
298.88%
3Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 8.53%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
37.94%
AR growth of 37.94% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
115.87%
Inventory growth of 115.87% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
-1.21%
Assets shrink while Drug Manufacturers - Specialty & Generic median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-5.72%
Negative BV/share change while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
41.69%
Debt growth of 41.69% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
-63.20%
R&D dropping while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
90.27%
SG&A growth far above Drug Manufacturers - Specialty & Generic median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.